2 May 2017

Verona Pharma Announces Closing of Global Offering

LONDON, May 02, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with signific…

Read more

26 April 2017

Verona Pharma Announces Pricing of Global Offering and Approval to List on the NASDAQ Global Market

5 April 2017

[ENCRYPTED]

[ENCRYPTED]

Read more

4 April 2017

Verona Pharma Doses First Patient in Phase 2a Clinical Trial Evaluating RPL554 for Cystic Fibrosis

Read more

4 April 2017

Verona Pharma Files Registration Statement for Proposed Global Offering

Read more

20 March 2017

2016 Annual Report and Accounts and Notice of AGM

Read more

8 February 2017

Result of General Meeting Consolidation of Share Capital

Read more

18 January 2017

Shareholder Circular for proposed consolidation, authority to issue new shares, adoption of new Articles and Notice of Meeting on 8 February 2017

Read more

18 January 2017

Proposed new Articles for adoption at Meeting on 8 February 2017

Read more

Targeting unmet needs

384m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

Read more about COPD and CF in the unmet needs section of this website

Go

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Basic & Clinical Pharmacology & Toxicology

Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us